KLK3 and prostate carcinoma: In a phase II clinical trial on prostate cancer patients with biochemical recurrence after prostatectomy, patients who received oral administration of SFN showed a lengthening of the on-treatment prostate-specific antigen doubling time, compared to pre-treatment [76].